CNN Runs With ANOTHER Fake Story

If you happened to be unfortunate enough to see the latest CNN hit piece on Tom Price, you would be convinced that he is a criminal. Well, President-Elect Donald Trump’s nominees for Health and Human Services Secretary is anything but a criminal. CNN was careful to leave out all the pertinent details that would clear him. Who bought these shares for Mr. Price? How many shares were purchased? How could this possibly be insider trading? The world looks at CNN and just wonders!

As Written By Jay Caruso for Red State:

If you look at this story by CNN about Representative Tom Price, it makes the incident look like some convoluted insider-trading scheme where Tom Pricey profited handsomely by proposing legislation to benefit a health care company he invested in just a week before. 

Rep. Tom Price last year purchased shares in a medical device manufacturer days before introducing legislation that would have directly benefited the company, raising new ethics concerns for President-elect Donald Trump’s nominee for Health and Human Services secretary.

Price bought between $1,001 to $15,000 worth of shares last March in Zimmer Biomet, according to House records reviewed by CNN.

Less than a week after the transaction, the Georgia Republican congressman introduced the HIP Act, legislation that would have delayed until 2018 a Centers for Medicare and Medicaid Services (CMS) regulation that industry analysts warned would significantly hurt Zimmer Biomet financially once fully implemented.

If you watch the accompanying video, Erin Burnett says the timeline of all this “this raises significant questions” to which Manu Raju replies, “Indeed it does …..


CNN Runs With An Absurd ‘Raises Questions’ Story About Trump’s Pick For HHS, Rep. Tom Price | RedState


Leave a Comment

We have no tolerance for comments containing violence, racism, vulgarity, profanity, all caps, or discourteous behavior. Thank you for partnering with us to maintain a courteous and useful public environment where we can engage in reasonable discourse.